⌘K
Loading ticker…
As of 2026-08-24, Cocrystal Pharma, Inc. Common Stock (COCP) has a 3-month relative strength percentile of 41 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 48. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 8.2%, relative volume 0.54×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
COCP is in a stage 1 base, week 1. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 10.3% / 2.3%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
COCP is held by 2 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $189K notional.
Held by 2 ETFs · $242K across latest filings · largest weight 0.00% (VXF).
Top 2 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $189K | — |
| VXFVanguard Extended Market ETF | 0.00% | $53K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | COCP Jan avg: 8.89% median: -0.68% win: 50% σ: 24.05% n: 4 2022-04-12 → 2026-07-31 | COCP Feb avg: -11.71% median: -11.56% win: 25% σ: 15.55% n: 4 2022-04-12 → 2026-07-31 | COCP Mar avg: -5.44% median: -2.95% win: 25% σ: 8.67% n: 4 2022-04-12 → 2026-07-31 | COCP Apr avg: 15.08% median: 10.71% win: 80% σ: 18.80% n: 5 2022-04-12 → 2026-07-31 | COCP May avg: 1.87% median: -12.90% win: 40% σ: 27.58% n: 5 2022-04-12 → 2026-07-31 | COCP Jun avg: -0.58% median: 1.99% win: 60% σ: 9.12% n: 5 2022-04-12 → 2026-07-31 | COCP Jul avg: -2.92% median: -2.07% win: 40% σ: 16.98% n: 5 2022-04-12 → 2026-07-31 | COCP Aug avg: -1.60% median: -2.95% win: 25% σ: 11.00% n: 4 2022-04-12 → 2026-07-31 (current) | COCP Sep avg: -20.99% median: -22.04% win: 0% σ: 15.17% n: 4 2022-04-12 → 2026-07-31 | COCP Oct avg: -12.44% median: -10.68% win: 25% σ: 12.36% n: 4 2022-04-12 → 2026-07-31 | COCP Nov avg: 8.88% median: 10.80% win: 75% σ: 8.24% n: 4 2022-04-12 → 2026-07-31 | COCP Dec avg: -12.01% median: -8.50% win: 0% σ: 11.62% n: 4 2022-04-12 → 2026-07-31 |